Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 10/20 | 0.55 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.55 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.55 |
| ▸ | GGH | Q92820 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | TET2 | Q6N021 | 3/20 | 0.41 |
| ▸ | KDM4A | O75164 | 2/20 | 0.41 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.41 |
| ▸ | KDM2A | Q9Y2K7 | 2/20 | 0.41 |
| ▸ | TET3 | O43151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575587 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL9696087 | 1.00 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Hydrochloric Acid SCHEMBL5575602 | 0.98 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| Hydrochloric Acid SCHEMBL5575609 | 0.98 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGHCYP1A2 | |
| SCHEMBL25254699 | 0.93 | FOLH1 (0.48) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL9697168 | 0.89 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL29324448 | 0.89 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL9696078 | 0.89 | FOLH1 (0.55) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL7257519 | 0.87 | FOLH1 (0.56) | FOLH1NAALAD2RIMKLAGGH | |
| SCHEMBL6237815 | 0.86 | FOLH1 (0.53) | FOLH1NAALAD2RIMKLAGGHCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118638410-A | Magnetic nano-particle and preparation method and application thereof | 首都医科大学 | 2024-09-13 | — | — | CN | claimed |
| CN-118005916-A | Modified polyamino acid derivative with conformational regulating capability, preparation and application thereof | 四川大学 | 2024-05-10 | — | — | CN | claimed |
| CN-116283636-A | Method for synthesizing Degu insulin side chain | 安徽盈科生物科技有限公司 | 2023-06-23 | — | — | CN | claimed |
| US-5952497-A | USEFUL IN PEPTIDE, POLYPEPTIDE AND PROTEIN SYNTHESIS | UNIVERSITY OF GEORGIA RESEARCH FOUNDATION (US) | 1999-09-14 | — | — | US | claimed |
| US-20250257045-A1 | CAGED GLUTAMATE UNLEASHED BY BLUE AND GREEN LIGHT: INNOVATIVE PHOTOSENSITIVE CONTROL | FLORIDA INSTITUTE OF TECH INC (US) | 2025-08-14 | — | — | US | disclosed |
| CN-120022382-A | Polyamino acid nanoparticle with lung targeting property, and preparation method and application thereof | 苏州大学 | 2025-05-23 | — | — | CN | disclosed |
| CN-119677795-A | Amphiphilic poly (amino acid) linear block copolymers and nanoparticles thereof for drug delivery applications | 纳诺瑟拉生物科学股份有限公司 | 2025-03-21 | — | — | CN | disclosed |
| CN-118638410-A | Magnetic nano-particle and preparation method and application thereof | 首都医科大学 | 2024-09-13 | — | — | CN | disclosed |
| CN-118401255-A | Paclitaxel conjugated compounds, pharmaceutical compositions comprising the same, and methods of use thereof | N1生命股份有限公司 | 2024-07-26 | — | — | CN | disclosed |
| CN-118284435-A | Drug conjugate based on epsilon-poly-L-lysine, intermediate and application thereof | 上海弼领生物技术有限公司 | 2024-07-02 | — | — | CN | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | Sumitomo Pharma Co., Ltd. (JP) | 2024-06-25 | — | — | US | disclosed |
| EP-0663840-A1 | PREPARATION OF FURTHER DIAGNOSTIC AGENTS | Andaris Limited (GB) | 1995-07-26 | — | — | EP | disclosed |
| EP-0458745-B1 | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography | BRACCO INT BV (NL) | 1994-09-28 | — | — | EP | disclosed |
| WO-1994008627-A1 | PREPARATION OF FURTHER DIAGNOSTIC AGENTS | ANDARIS LIMITED (GB) | 1994-04-28 | — | — | WO | disclosed |
| EP-0587311-A1 | Peptides capable of inhibiting the activity of HIV protease, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1994-03-16 | — | — | EP | disclosed |
| EP-0533886-A1 | PREPARATION OF DIAGNOSTIC AGENTS | Delta Biotechnology Limited (GB) | 1993-03-31 | — | — | EP | disclosed |
| EP-0512693-A1 | Preparation of diagnostic agents | Andaris Limited (GB) | 1992-11-11 | — | — | EP | disclosed |
| WO-1992018164-A1 | PREPARATION OF DIAGNOSTIC AGENTS | DELTA BIOTECHNOLOGY LIMITED (GB) | 1992-10-29 | — | — | WO | disclosed |
| EP-0458745-A1 | Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography | BRACCO International B.V. (NL) | 1991-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250257045-A1 | CAGED GLUTAMATE UNLEASHED BY BLUE AND GREEN LIGHT: INNOVATIVE PHOTOSENSITIVE CONTROL | GRIA4, GAP43, GGH | FOLH1 98/4885NAALAD2 184/4885RIMKLA 244/4885 |
| US-12018093-B2 | Hemiasterlin derivatives and antibody-drug conjugates including same | FCGRT, QARS1, INHA | FOLH1 4072/4885NAALAD2 984/4885RIMKLA 1754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.